Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Impact · against what's priced in

The news is largely noise for Moderna and BioNTech, as the market has already priced in mRNA platform volatility and the COVID-19 revenue collapse. Pfizer's guidance raise is a positive update on margin discipline, while Merck's trial launch is an early-stage event that doesn't move the needle on its current valuation.

BNTX−0.10

Already priced in

The price assumes

COVID-19 revenue collapse is the dominant reality